{"id":288,"date":"2025-07-17T18:18:58","date_gmt":"2025-07-17T18:18:58","guid":{"rendered":"https:\/\/dexalumpotrik.com\/?p=288"},"modified":"2025-07-21T13:18:19","modified_gmt":"2025-07-21T13:18:19","slug":"fda-reverses-ban-on-sale-of-juul-e-cigarettes","status":"publish","type":"post","link":"https:\/\/dexalumpotrik.com\/index.php\/2025\/07\/17\/fda-reverses-ban-on-sale-of-juul-e-cigarettes\/","title":{"rendered":"FDA reverses ban on sale of Juul e-cigarettes"},"content":{"rendered":"
The Food and Drug Administration (FDA) has authorized Juul Labs<\/a> to keep its electronic cigarettes on the market, a major reversal after the agency completely banned<\/a> the company’s products in 2022. <\/p>\n The agency said Thursday it will allow the sale of Juul\u2019s original e-cigarette device as well as refill cartridges in tobacco and menthol flavors. The move followed \u201can extensive scientific review\u201d that showed the benefit to adult smokers outweighed the risk to young people or adults who don\u2019t smoke. <\/p>\n FDA said Juul submitted evidence showing high rates of adults completely switching from cigarettes to either the tobacco- or menthol-flavored Juul products. <\/p>\n \u201cWhile today\u2019s actions permit these specific e-cigarette products to be legally marketed in the U.S. to adults 21 and older, it does not mean these tobacco products are safe, nor are they FDA approved,\u201d the agency said. <\/p>\n FDA\u2019s decision marks the latest chapter for a company so popular it was once synonymous with vaping. But as more young people began using its fruit flavored products<\/a>, federal scrutiny grew. <\/p>\n Juul has denied allegations that it marketed<\/a> its e-cigarettes to children and teens. <\/p>\n The FDA in 2022 announced a ban on the sale of Juul e-cigarettes<\/a> nationwide, saying the company did not prove that keeping its products on the market \u201cwould be appropriate for the protection of the public health.\u201d <\/p>\n The agency suspended the order about two weeks later to conduct an internal review of \u201cscientific issues\u201d in the company\u2019s application. <\/p>\n Despite the pause, FDA\u2019s actions\u00a0nearly bankrupted the company. The e-cigarette maker also subsequently paid $1.7 billion<\/a> to resolve thousands of lawsuits alleging the company aggressively marketed its e-cigarettes to young people and fueled a vaping crisis.\u00a0<\/p>\n